Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Current drug metabolism

• Publication date

  2010-10-31

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.2174/138920010794328922PMID 21189139
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Species Difference in the Effect of Grapefruit Juice on Intestinal Absorption of Talinolol between Human and Rat

  2010cited by this paper
• Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

  2010cited by this paper
• Model Analysis of the Concentration-Dependent Permeability of P-gp Substrates

  2010cited by this paper
• Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans.

  2010cited by this paper
• Quantitative Prediction of Intestinal Metabolism in Humans from a Simplified Intestinal Availability Model and Empirical Scaling Factor

  2010cited by this paper
• Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.

  2010cited by this paper
• Confidence Assessment of the Simcyp Time-Based Approach and a Static Mathematical Model in Predicting Clinical Drug-Drug Interactions for Mechanism-Based CYP3A Inhibitors

  2010cited by this paper
• Membrane transporters in drug development

  2010cited by this paper
• Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption.

  2009cited by this paper
• Interplay of transporters and enzymes in drug and metabolite processing.

  2009cited by this paper
• Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.

  2009cited by this paper
• Drug–Drug Interactions Mediated Through P‐Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug

  2009cited by this paper
• Simulations of the Nonlinear Dose Dependence for Substrates of Influx and Efflux Transporters in the Human Intestine

  2009cited by this paper
• Method for predicting the risk of drug–drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein

  2009cited by this paper
• Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane.

  2008cited by this paper
• Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions

  2008cited by this paper
• The Quantitative Prediction of CYP-mediated Drug Interaction by Physiologically Based Pharmacokinetic Modeling

  2008cited by this paper
• A regulatory viewpoint on transporter-based drug interactions.

  2008cited by this paper
• A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients

  2007cited by this paper
• Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts

  2007cited by this paper
• Prediction of intestinal first-pass drug metabolism.

  2007cited by this paper
• Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs.

  2007cited by this paper
• BINDING OF DRUGS TO HEPATIC MICROSOMES: COMMENT AND ASSESSMENT OF CURRENT PREDICTION METHODOLOGY WITH RECOMMENDATION FOR IMPROVEMENT

  2006cited by this paper
• In Silico Modeling of Non-Linear Drug Absorption for the P-gp Substrate Talinolol and of Consequences for the Resulting Pharmacodynamic Effect

  2006cited by this paper
• A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.

  2006cited by this paper
• Lack of Dose-Dependent Effects of Itraconazole on the Pharmacokinetic Interaction with Fexofenadine

  2006cited by this paper
• The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions

  2006cited by this paper
• THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”

  2006cited by this paper
• The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins.

  2006cited by this paper
• Prediction of In Vivo Drug-Drug Interactions from In Vitro Data

  2006cited by this paper
• PREDICTION OF TIME-DEPENDENT CYP3A4 DRUG-DRUG INTERACTIONS: IMPACT OF ENZYME DEGRADATION, PARALLEL ELIMINATION PATHWAYS, AND INTESTINAL INHIBITION

  2006cited by this paper
• Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.

  2006cited by this paper
• Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors

  2005cited by this paper
• CITRUS JUICES INHIBIT THE FUNCTION OF HUMAN ORGANIC ANION-TRANSPORTING POLYPEPTIDE OATP-B

  2005cited by this paper
• Effect of Grapefruit Juice Volume on the Reduction of Fexofenadine Bioavailability: Possible Role of Organic Anion Transporting Polypeptides

  2005cited by this paper
• Cytochrome P450 3A expression and activity in the human small intestine

  2004cited by this paper
• Comparative Bioavailability Study of Two Tablet Formulations of Digoxin

  2004cited by this paper
• Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.

  2004cited by this paper
• Intravenous and oral alfentanil as in vivo probes for hepatic and first‐pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis

  2004cited by this paper
• Unmasking the dynamic interplay between efflux transporters and metabolic enzymes.

  2004cited by this paper
• CYP3A4-Transfected Caco-2 Cells as a Tool for Understanding Biochemical Absorption Barriers: Studies with Sirolimus and Midazolam

  2004cited by this paper
• Cytochrome P450 3A4 and P‐glycoprotein Expression in Human Small Intestinal Enterocytes and Hepatocytes: A Comparative Analysis in Paired Tissue Specimens

  2004cited by this paper
• Transport Characteristics of Fexofenadine in the Caco-2 Cell Model

  2004cited by this paper
• Isolation and Characterization of Caco-2 Subclones Expressing High Levels of Multidrug Resistance Protein Efflux Transporter

  2003cited by this paper
• Inhibition of P-Glycoprotein by Newer Antidepressants

  2003cited by this paper
• The effects of fruit juices on drug disposition: a new model for drug interactions

  2003cited by this paper
• The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

  2003cited by this paper
• Efflux Ratio Cannot Assess P-Glycoprotein-Mediated Attenuation of Absorptive Transport: Asymmetric Effect of P-Glycoprotein on Absorptive and Secretory Transport Across Caco-2 Cell Monolayers

  2003cited by this paper
• Dipyridamole enhances digoxin bioavailability via P‐glycoprotein inhibition

  2003cited by this paper
• Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption.

  2003cited by this paper
• Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.

  2003cited by this paper
• Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series).

  2003cited by this paper
• Interaction of Common Azole Antifungals with P Glycoprotein

  2002cited by this paper
• Are MDCK Cells Transfected with the Human MDR1 Gene a Good Model of the Human Intestinal Mucosa?

  2002cited by this paper
• Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.

  2002cited by this paper
• Pharmacokinetics and Interactions of a Novel Antagonist of Chemokine Receptor 5 (CCR5) with Ritonavir in Rats and Monkeys: Role of CYP3A and P-Glycoprotein

  2002cited by this paper
• C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.

  2002cited by this paper
• Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.

  2002cited by this paper
• Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression.

  2002cited by this paper
• Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein

  2001cited by this paper
• Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein.

  2001cited by this paper
• Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.

  2001cited by this paper
• Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.

  2001cited by this paper
• Predicting the impact of physiological and biochemical processes on oral drug bioavailability.

  2001cited by this paper
• Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein

  2001cited by this paper
• P‐glycoprotein Interactions of Nefazodone and Trazodone in Cell Culture

  2001cited by this paper
• HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein

  2001cited by this paper
• A Functional Assay for Quantitation of the Apparent Affinities of Ligands of P-Glycoprotein in Caco-2 Cells

  2001cited by this paper
• First-pass disposition of (-)-6-aminocarbovir in rats: II. Inhibition of intestinal first-pass metabolism.

  2000cited by this paper
• Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.

  2000cited by this paper
• Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.

  2000cited by this paper
• Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter.

  2000cited by this paper
• Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.

  2000cited by this paper
• Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P‐glycoprotein

  2000cited by this paper
• Fexofenadine

  2000cited by this paper
• Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.

  2000cited by this paper
• PSC833, cyclosporin A, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts.

  1999cited by this paper
• Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes.

  1999cited by this paper
• Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.

  1999cited by this paper
• Effects of Intestinal CYP3A4 and P-Glycoprotein on Oral Drug Absorption—Theoretical Approach

  1999cited by this paper
• CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

  1999cited by this paper
• Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam

  1998cited by this paper
• Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole

  1998cited by this paper
• Inhibitory Effects of a Cyclosporin Derivative, SDZ PSC 833, on Transport of Doxorubicin and Vinblastine via Human P‐Glycoprotein

  1998cited by this paper
• Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem

  1998cited by this paper
• The area under the plasma concentration–time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin

  1998cited by this paper
• Itraconazole greatly increases plasma concentrations and effects of felodipine

  1997cited by this paper
• In vivo assessment of intestinal drug metabolism.

  1997cited by this paper
• Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.

  1997cited by this paper
• Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A.

  1997cited by this paper
• Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay.

  1996cited by this paper
• Evidence for Intestinal Secretion as an Additional Clearance Pathway of Talinolol Enantiomers: Concentration- and Dose-dependent Absorption in Vitro and in Vivo

  1996cited by this paper
• The Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Midazolam

  1996cited by this paper
• The effect of ingestion time interval on the interaction between itraconazole and triazolam

  1996cited by this paper
• Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

  1995cited by this paper
• Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

  1995cited by this paper
• Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

  1994cited by this paper
• The bioavailability of digoxin from three oral formulations measured by a specific h.p.l.c. assay.

  1993cited by this paper
• Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine.

  1987cited by this paper
• Glucuronidation of morphine and six beta 2-sympathomimetics in isolated rat intestinal epithelial cells.

  1985cited by this paper

• Investigation of differentiation conditions for canine duodenum, upper jejunum, and ileum crypt-derived cells for drug transport and metabolism.

  2025cites this paper
• The regulatory effects of mitragynine on P-glycoprotein transporter.

  2024cites this paper
• Glycyrrhizin protects against diosbulbin B‐induced hepatotoxicity by inhibiting the metabolic activation of diosbulbin B

  2023cites this paper
• Evaluation of Pharmacokinetic Drug–Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches

  2021cites this paper
• Cytochrome P450 and P-gp Mediated Herb-Drug Interactions and Molecular Docking Studies of Garcinol

  2021cites this paper
• A REVIEW ON NOSE TO BRAIN DRUG DELIVERY SYSTEM

  2021cites this paper
• Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development.

  2020cites this paper
• Characterization of the Human Intestinal Drug Transport with Ussing Chamber System Incorporating Freshly Isolated Human Jejunum

  2020cites this paper
• Predicting the effect of tea polyphenols on ticagrelor by incorporating transporter-enzyme interplay mechanism.

  2020cites this paper
• Evaluation of In Vitro Models for Assessment of Human Intestinal Metabolism in Drug Discovery

  2020cites this paper
• Dioscorea bulbifera L. delays the excretion of doxorubicin and aggravates doxorubicin-induced cardiotoxicity and nephrotoxicity by inhibiting the expression of P-glycoprotein in mice liver and kidney

  2019cites this paper
• A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab

  2019cites this paper
• The inhibitory effects of mitragynine on P-glycoprotein in vitro

  2019cites this paper
• Discovery of aromatic amides with triazole-core as potent reversal agents against P-glycoprotein-mediated multidrug resistance.

  2019cites this paper
• Development of a LC–MS/MS method to investigate the interference of pharmacokinetics of the main constituents in Saxifraga stolonifera: Involvement of drug metabolism enzymes

  2018cites this paper
• Intestinal absorption of pallidifloside D are limited by P-glycoprotein in mice

  2018cites this paper
• Navigating Transporter Sciences in Pharmacokinetics Characterization Using the Extended Clearance Classification System

  2018cites this paper
• Impact of P-Glycoprotein on Intestinal Absorption of an Inhibitor of Apoptosis Protein Antagonist in Rats: Mechanisms of Nonlinear Pharmacokinetics and Food Effects

  2018cites this paper
• Lipid Nanoparticles for Nasal/Intranasal Drug Delivery.

  2017cites this paper
• The potential of Epimedium koreanum Nakai for herb–drug interaction

  2017cites this paper
• Mechanistic understanding of the effect of Dengzhan Shengmai capsule on the pharmacokinetics of clopidogrel in rats.

  2016cites this paper
• ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy.

  2016cites this paper
• Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System

  2016cites this paper
• Meclizine, a pregnane X receptor agonist, is a direct inhibitor and mechanism-based inactivator of human cytochrome P450 3A.

  2015cites this paper
• Effects of Drug Transporters on Pharmacological Responses and Safety.

  2015cites this paper
• The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations

  2015cites this paper
• Mechanism-based inhibition of Alantolactone on human cytochrome P450 3A4 in vitro and activity of hepatic cytochrome P450 in mice.

  2015cites this paper
• Potential drug interactions associated with glycyrrhizin and glycyrrhetinic acid

  2015cites this paper
• Beaned: Fatal forty DDI: Diltiazem, tacrolimus, CYP3A4, P-glycoprotein

  2015cites this paper
• P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats

  2014cites this paper
• INTERACTIONS BETWEEN DRUGS OF ABUSE AND HIV PROTEASE INHIBITORS

  2014cites this paper
• Nasal Delivery of Biopharmaceuticals

  2014cites this paper
• Inhibiton of cytochrome P450 isoenzymes and P-gp activity by multiple extracts of Huang-Lian-Jie-Du decoction.

  2014cites this paper
• Novel pre-clinical methodologies for pharmacokinetic drug–drug interaction studies: spotlight on “humanized” animal models

  2014cites this paper
• The Importance of Villous Physiology and Morphology in Mechanistic Physiologically-Based Pharmacokinetic Models

  2014cites this paper
• Planar bioadhesive microdevices: a new technology for oral drug delivery.

  2014cites this paper
• Clarification of P-glycoprotein inhibition-related drug–drug interaction risks based on a literature search of the clinical information

  2014cites this paper
• Mechanisms and Genetics of Drug Transport

  2013cites this paper
• Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human

  2013cites this paper
• DMD054031 1975..1993

  2013cites this paper
• Screening Compounds with a Novel High-Throughput ABCB1-Mediated Efflux Assay Identifies Drugs with Known Therapeutic Targets at Risk for Multidrug Resistance Interference

  2013cites this paper
• Mass Spectrometry-Based Targeted Proteomics as a Tool to Elucidate the Expression and Function of Intestinal Drug Transporters

  2013influential citation
• Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.

  2013cites this paper
• Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function.

  2013cites this paper
• Pharmacokinetic Interaction between Losartan and Rhodiola rosea in Rabbits

  2013cites this paper
• A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development

  2013cites this paper
• Long-lasting inhibition of the intestinal absorption of fexofenadine by cyclosporin A in rats.

  2012cites this paper
• Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus.

  2012cites this paper
• Mechanisms underlying food-drug interactions: inhibition of intestinal metabolism and transport.

  2012cites this paper
• Intestinal transporters for endogenic and pharmaceutical organic anions: the challenges of deriving in‐vitro kinetic parameters for the prediction of clinically relevant drug–drug interactions

  2012cites this paper
• Effect of TSHAC on human cytochrome P450 activity, and transport mediated by P-glycoprotein.

  2012cites this paper
• INDI: a computational framework for inferring drug interactions and their associated recommendations

  2012cites this paper
• Drug Interactions with Herbal Medicines

  2012cites this paper
• Prediction of Nonlinear Intestinal Absorption of CYP3A4 and P-Glycoprotein Substrates from their In Vitro Km Values

  2012cites this paper
• Establishment of a stable human cell line, HPL-A3, for use in reporter gene assays of cytochrome P450 3A inducers.

  2012cites this paper
• Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids.

  2012cites this paper
• Why we need proper PBPK models to examine intestine and liver oral drug absorption.

  2012cites this paper
• Role of P-Glycoprotein Expression and Function in Cystinotic Renal Proximal Tubular Cells

  2011cites this paper
• In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences

  2011cites this paper